Bristol Myers Squibb to appeal against Irish court ruling over €11bn drug Eliquis

Pharma company battles rivals over generic versions of its blood-clot medicine

Bristol Myers Squibb chief Chris Boerner. Photo: Bloomberg

John Mulligan

Pharmaceutical giant Bristol Myers Squibb (BMS) intends to appeal against a decision by Ireland’s High Court issued in December that deemed a patent connected to its Eliquis medicine used to treat blood clots is invalid.

However, given a decision in the UK courts made last October found against BMS, the company might struggle to successfully win over the courts in Ireland.